FONAR Announces Reverse Stock
              Split
                         MELVILLE,
                 NEW YORK, April 17, 2007 - FONAR Corporation (NASDAQ-FONR),
                
                  The Inventor of MR Scanning™,
today announced that following its annual meeting of stockholders held yesterday,
                  it has effected a reverse stock split at a ratio of 1:25 (one
                  new share for every 25 shares) of its outstanding common stock
                  and all other classes of its outstanding stock, effective April
                  17, 2007. 
          In accordance with
normal NASDAQ procedures related to reverse stock splits, NASDAQ will append
a “D” to the symbol to become (FONRD) for a period of approximately
20 trading days. Afterwards, at the open of business on May 15, 2007, NASDAQ
will remove the “D” and the symbol will be (FONR) as before.
                  
          As a result of the
hearing held before the NASDAQ Listing Qualifications Panel (“Panel”)
on February 15, 2007, FONAR’s request for continued listing on The NASDAQ
Stock Market was granted, subject to the condition that on or before May 1, 2007,
the Company must have evidenced a closing bid price of $1.00 or more for a minimum
of ten consecutive trading days. The Panel’s decision was based on its
determination that the reverse stock split to be presented at the Annual Meeting
on April 16, 2007, when implemented, would be likely to cure the bid price deficiency
and allow the Company to maintain compliance for the longer term. Accordingly,
the company has effected a reverse stock split today.               
               
About FONAR
              
FONAR® was incorporated in 1978, making it
                the first, oldest and most experienced MRI manufacturer in the
                industry. FONAR
                 introduced the world's first commercial MRI in 1980, and went
                 public in 1981. Since its inception, FONAR has installed hundreds
                 of MRI scanners worldwide. Their stellar product line includes
                 the FONAR UPRIGHT™ Multi-Position™ MRI (also known
                 as the STAND-UP™ MRI), the only whole-body MRI that performs
                 Multi-Position™ imaging (mpMRI™) and scans patients
                 in numerous weight-bearing positions, i.e. standing, sitting,
                 in
                 flexion and extension, as well as the conventional lie-down
                 position. The FONAR UPRIGHT™ Multi-Position™ MRI
                 often sees the patient's problem that other scanners cannot
                 because
                 they are lie-down only. With nearly one half million patients
                 scanned, the patient-friendly FONAR UPRIGHT™ Multi-Position™                MRI
                 has a near zero claustrophobic rejection rate by patients. A
                 radiologist said, "FONAR UPRIGHT™ MRI – No
                 More Claustrophobia - The Tunnel Is Gone." As another FONAR
                 customer states, "If the patient is claustrophobic in this
                 scanner, they'll be claustrophobic in my parking lot." Approximately
                 85% of patients are scanned sitting while they watch a 42" flat
                 screen TV. FONAR's latest MRI scanner is the FONAR 360™,
                 a room-size recumbent scanner that optimizes openness while
                 facilitating physician access to the patient. FONAR is headquartered
              on Long Island, New York, and has approximately 400 employees.
            
            
              #
                The Inventor of MR Scanning™,
                Full Range of Motion™, STAND-UP™, UPRIGHT™,
                Multi-Position™, pMRI™, True Flow™, Walk-In™ and
                The Proof is in the Picture™ are trademarks of FONAR Corporation.
              This release may include 
                forward-looking statements from the company that may or may not 
                materialize. Additional information on factors that could potentially 
                affect the company's financial results may be found in the company's 
                filings with the Securities and Exchange Commission. 
                ###